Mike Watts, MD, FSIR, discusses his presentation on the use of wearables and artificial intelligence in the prevention and treatment of chronic limb-threatening ischemia.
Mike Watts, MD, FSIR, discusses his presentation on the use of wearables and artificial intelligence in the prevention and treatment of chronic limb-threatening ischemia.
Dr Ramon Varcoe discusses his ISET 2025 presentation on the efficacy and safety of bioresorbable drug-coated balloons in treating infrapopliteal arterial disease.
Dr Ramon Varcoe discusses his ISET 2025 presentation on the efficacy and safety of bioresorbable drug-coated balloons in treating infrapopliteal arterial disease.
In this video recorded at AMP 2024, Dr. Ramon Varcoe discusses 2 of his AMP presentations on the results and indications of the LIFE-BTK and RESOLV studies.
In this video recorded at AMP 2024, Dr. Ramon Varcoe discusses 2 of his AMP presentations on the results and indications of the LIFE-BTK and RESOLV studies.
Dr. Alik Farber discusses his ISET 2024 presentation on the BEST-CLI and BASIL-2 trials and how to best manage patients with CLTI in the wake of these trials.
Dr. Alik Farber discusses his ISET 2024 presentation on the BEST-CLI and BASIL-2 trials and how to best manage patients with CLTI in the wake of these trials.
“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary,” said Joo-Yong Hahn, MD.
“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary,” said Joo-Yong Hahn, MD.
The study followed nearly 12,000 adults for approximately 16 years. Investigators applied AI to participants' standard coronary artery calcium scans to measure fat surrounding the heart.
The study followed nearly 12,000 adults for approximately 16 years. Investigators applied AI to participants' standard coronary artery calcium scans to measure fat surrounding the heart.
In July, Leapfrog will publicly report patient safety and quality data on thousands more ASCs on its website, allowing patients, purchasers and employers to search by procedure and compare ASCs side-by-side on evidence-based safety and...
In July, Leapfrog will publicly report patient safety and quality data on thousands more ASCs on its website, allowing patients, purchasers and employers to search by procedure and compare ASCs side-by-side on evidence-based safety and...
Treatment with enlicitide resulted in statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe at eight weeks (day 56)...
Treatment with enlicitide resulted in statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe at eight weeks (day 56)...
The study utilized Tempus Next, an AI platform that identifies significant AS or MR patients who may meet guideline-indicated therapy criteria, but do not have a treatment plan in place.
The study utilized Tempus Next, an AI platform that identifies significant AS or MR patients who may meet guideline-indicated therapy criteria, but do not have a treatment plan in place.
The new TRISCEND II trial data presented during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system.
The new TRISCEND II trial data presented during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system.
In a statement, Drs. Martin Leon, Ajay Kirtane, William Fearon, and Allen Jeremias stated: "The compelling results should serve as the impetus to increase adoption of physiology worldwide."
In a statement, Drs. Martin Leon, Ajay Kirtane, William Fearon, and Allen Jeremias stated: "The compelling results should serve as the impetus to increase adoption of physiology worldwide."
At the American College of Cardiology (ACC) 2026 Scientific Session, Boston Scientific presented results from two late-breaking randomized controlled trials evaluating device-based approaches in cardiovascular care: CHAMPION-AF, studying the...
At the American College of Cardiology (ACC) 2026 Scientific Session, Boston Scientific presented results from two late-breaking randomized controlled trials evaluating device-based approaches in cardiovascular care: CHAMPION-AF, studying the...
MOMENTUM is described as the first U.S.-based study and the largest study to date to assess the prevalence of hypercortisolism among individuals with resistant hypertension. Researchers analyzed 1,086 participants across 50 centers in the...
MOMENTUM is described as the first U.S.-based study and the largest study to date to assess the prevalence of hypercortisolism among individuals with resistant hypertension. Researchers analyzed 1,086 participants across 50 centers in the...
